A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria Patient must have a histologically confirmed diagnosis of Kaposi's sarcoma. Positive antibody to HIV confirmed by ELISA or Western blot on the same serum. Exclusion Criteria Active drug or alcohol abuse. Co-existing Condition: Patients with the following complications are excluded: Active opportunistic infections requiring ongoing therapy. Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. Concurrent neoplasms other than basal cell carcinoma of skin. Known sensitivity to polymycin or neomycin. Patients with the following complications are excluded: Active opportunistic infections requiring ongoing therapy. Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. Concurrent neoplasms other than basal cell carcinoma of skin. Known sensitivity to polymycin or neomycin. Prior Medication: Excluded: Any prior zidovudine (AZT) or interferon alpha protocol participation. Excluded within 30 days of study entry: Immunomodulating agents. Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives. Excluded within 90 days of study entry: Antiretroviral agents. Treatment of Pneumocystis carinii pneumonia (PCP). Prior Treatment: Excluded within 30 days of study entry: Radiation therapy.